On March 9, 2017 Xenetic Biosciences, Inc. (NASDAQ: XBIO) ("Xenetic" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics, reported that M. Scott Maguire, Xenetic’s Chief Executive Officer will present at the 29th Annual ROTH Conference on Tuesday, March 14th at 11:30 a.m. PT in Dana Point, CA (Press release, Xenetic Biosciences, MAR 9, 2017, View Source [SID1234537804]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
During his presentation, Mr. Maguire will provide a corporate update and will discuss the Company’s license deal with Shire plc (LSE: SHP, NASDAQ: SHPG), a significant stockholder of the Company, along with the clinical status of the product candidate PSA-Recombinant SHP656 (Factor VIII) being developed as a long-acting therapeutic for the treatment of hemophilia utilizing Xenetic’s proprietary PolyXen platform technology. Xenetic has the potential to receive from Shire up to $100 million in cash milestones plus royalties linked to sales.
Mr. Maguire will also discuss the Company’s clinical and regulatory progress for its in-house product candidate, XBIO-101 (sodium cridanimod), currently in development for the treatment of progesterone resistant endometrial cancer.
A live webcast of the presentation will be available by accessing the IR Calendar in the Investors section of Xenetic’s website (www.xeneticbio.com). A replay of the webcast will be available for 90 days, starting approximately two hours after the presentation ends.